Search Nerddpedia

Monoclonal Antibodies

Monoclonal antibodies (mAbs) are laboratory-produced molecules engineered to recognize and bind to specific targets, revolutionizing the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. ## Overview Monoclonal antibodies are a type of immunotherapy that harnesses the power of the immune system to fight diseases. These molecules are designed to mimic the structure of natural antibodies, which are proteins produced by the immune system to recognize and neutralize pathogens. In contrast to traditional antibodies, which are produced by the immune system in response to a specific antigen, monoclonal antibodies are produced in a laboratory using a process called hybridoma technology. This allows for the production of large quantities of antibodies with a specific binding affinity for a particular target. Monoclonal antibodies work by binding to specific targets on the surface of cells, such as cancer cells or infected cells, and triggering an immune response that leads to the destruction of these cells. They can also be engineered to deliver therapeutic payloads, such as chemotherapy agents or radioactive isotopes, directly to cancer cells, reducing the harm to healthy cells. The use of monoclonal antibodies has transformed the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, offering new hope for patients with previously untreatable conditions. ## History/Background The concept of monoclonal antibodies dates back to the 1970s, when scientists first discovered that mice could produce antibodies against specific antigens. In 1975, Georges Köhler and César Milstein developed the hybridoma technology, which allows for the production of large quantities of monoclonal antibodies. This breakthrough led to the development of the first monoclonal antibody, OKT3, which was approved by the FDA in 1986 for the treatment of acute rejection in kidney transplant patients. Since then, numerous monoclonal antibodies have been developed and approved for various indications, including cancer, autoimmune disorders, and infectious diseases. ## Key Information Monoclonal antibodies have several key characteristics that make them effective therapeutic agents: * **Specificity**: Monoclonal antibodies are designed to bind to specific targets, reducing the risk of off-target effects. * **Affinity**: Monoclonal antibodies have a high affinity for their target, allowing them to bind with high specificity. * **Stability**: Monoclonal antibodies are stable molecules that can be stored for long periods without degradation. * **Efficacy**: Monoclonal antibodies have been shown to be effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Some of the most notable monoclonal antibodies include: * **Trastuzumab** (Herceptin): approved for the treatment of HER2-positive breast cancer * **Rituximab** (Rituxan): approved for the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis * **Adalimumab** (Humira): approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and Crohn's disease ## Significance Monoclonal antibodies have revolutionized the treatment of various diseases, offering new hope for patients with previously untreatable conditions. They have also transformed the field of medicine, enabling the development of targeted therapies that can selectively target specific cells or tissues. The use of monoclonal antibodies has also led to a better understanding of the immune system and its role in disease, paving the way for the development of new immunotherapies. INFOBOX: - Name: Monoclonal Antibodies - Type: Immunotherapy - Date: 1975 (hybridoma technology developed) - Location: University of Cambridge (UK) - Known For: Revolutionizing the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases TAGS: Immunotherapy, Monoclonal Antibodies, Cancer, Autoimmune Disorders, Infectious Diseases, Hybridoma Technology, Georges Köhler, César Milstein, Trastuzumab, Rituximab, Adalimumab.